A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Gold Standard Diagnostics Receives FDA 510K for Lyme IgG and IgM EIA Kits

October 5, 2020

Gold Standard Diagnostics Group (GSD) today announced the immediate availability of their two new Lyme IgG and Lyme IgM EIA kits for detection of antibodies against Lyme disease-causing bacteria. The two assays give laboratories a more diverse arsenal of testing methodologies that allows them to achieve more reliable results.

Gold Standard Diagnostics advises the assays are available immediately in the US.

The separate IgG and IgM assays provide laboratories the ability to offer more specificity in their Lyme screen algorithm. They are designed for optimal functionality in diagnostic laboratories with a total incubation time of 45 minutes at room temperature with ready-to-use controls. The kits can be run manually or on any open automated EIA platform.

While the world still grapples with COVID-19, many other medical conditions, including Lyme disease, are on the rise and are often undiagnosed. Experts have recently found, Americans infected with Lyme disease is ten times higher than what is reported by the CDC. What is more, symptoms of Lyme disease are so varied that it is often quite challenging to diagnose and can range from fever and headaches to irregular heartbeats, dizziness, and nerve pain. The GSD Lyme IgG and Lyme IgM EIA assays were made to provide antibody specific reliable information to the clinicians diagnosing this disease.

“We are witness to major changes in Lyme diagnostics. Our team of professionals are adapting and responding to these changes. New products are being produced to meet these new demands. GSD has an ever-expanding Lyme product menu to address and exceed laboratory expectations for Lyme and other tick-borne disease testing,” states Dr. Barry Menefee, Infectious Disease Specialist at GSD.

Traditional Lyme testing is our core. New and innovative Lyme testing will soon be available from GSD.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy